首页> 外文OA文献 >Randomized trial of a shared decision-making intervention consisting of trade-offs and individualized treatment information for BRCA1/2 mutation carriers.
【2h】

Randomized trial of a shared decision-making intervention consisting of trade-offs and individualized treatment information for BRCA1/2 mutation carriers.

机译:一项共享决策干预措施的随机试验,包括权衡和针对BRCA1 / 2突变携带者的个性化治疗信息。

摘要

PURPOSE: To evaluate a shared decision-making intervention (SDMI) for BRCA1/2 mutation carriers who have to make a choice between screening and prophylactic surgery for breasts and/or ovaries. PATIENTS AND METHODS: The SDMI consisted of two value assessment sessions, using the time trade-off method, followed by individualized treatment information based on (quality-adjusted) life expectancy. After the baseline assessment (2 weeks after a positive DNA test result), women were randomly assigned to the SDMI group (n = 44), receiving the SDMI 2 months after the test result, or to the control group (n = 44). The short- and long-term effects, 3 and 9 months after the test result, were assessed using questionnaires. Data were collected on well-being, treatment choice, and decision-related outcomes. RESULTS: In the short term, the SDMI had no effect. In the long term, with respect to well-being, patients in the SDMI group had less intrusive thoughts (P =.05) and better general health (P =.01) and tended to be less depressed (P =.07). With respect to decision-related outcomes for the breasts, the SDMI group held stronger preferences (P =.02) and agreed more strongly to having weighed the pros and cons (P =.01). No effect was found on treatment choice. In the long term, interaction effects between the SDMI and cancer history were found. The SDMI showed an overall beneficial effect for unaffected women, whereas affected women tended to experience detrimental effects. CONCLUSION: We conclude that the SDMI improved decision making in unaffected BRCA1/2 mutation carriers. Supporting decision making in a systematic way using trade-offs is beneficial for these women.
机译:目的:评估BRCA1 / 2突变携带者的共享决策干预措施(SDMI),这些携带者必须在乳房和/或卵巢的筛查和预防性手术之间做出选择。患者和方法:SDMI包括两个价值评估会议,使用时间权衡方法,然后是基于(质量调整的)预期寿命的个性化治疗信息。基线评估后(DNA检测结果阳性后2周),将妇女随机分配至SDMI组(n = 44),在检测结果后2个月接受SDMI,或随机分配至对照组(n = 44)。使用调查表评估测试结果后3个月和9个月的短期和长期影响。收集有关幸福感,治疗选择和决策相关结果的数据。结果:在短期内,SDMI无效。从长远来看,就福祉而言,SDMI组患者的侵入性思想较少(P = .05),总体健康状况较好(P = .01),而抑郁症则较少(P = .07)。关于与乳房有关的决定性结局,SDMI组拥有更强的偏好(P = .02),并更强烈地同意权衡利弊(P = .01)。未发现对治疗选择的影响。从长远来看,发现了SDMI和癌症病史之间的相互作用。 SDMI对未受影响的妇女显示出总体上的有益影响,而受影响的妇女往往会受到不利影响。结论:我们得出结论,SDMI改善了未受影响的BRCA1 / 2突变携带者的决策。通过权衡取舍有系统地支持决策对这些妇女是有益的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号